DGAP-News

MOLOGEN AG: MOLOGEN AG: Extension of TEACH study based on supportive first study results - Seite 2

cellular biology conference) from 20 - 24 March 2016 in Olympic Valley,
USA.

Abstract & Poster details:
Abstract title: "Toll-like receptor 9 enhancement of antiviral immunity in
chronic HIV-1 infection (TEACH)"

Poster:
Presentation: 24 March 2016, Poster session 4
Poster #: 4025
Poster Title: "Toll-like receptor 9 enhancement of antiviral immunity in
chronic HIV-1 infection (TEACH)"

For more information on the Keystone conference please visit:
http://www.keystonesymposia.org/

Furthermore, a publication is now available in the prestigious Journal of
Virology:
http://jvi.asm.org/search?fulltext=doi%3A10.1128%2FJVI.00222-16&submit=yes
&x=0&y=0

About TEACH
TEACH (Toll-like receptor 9 enhancement of antiviral immunity in chronic
HIV infection) is a non-randomized interventional phase I/IIa trial of
lefitolimod (MGN1703) in HIV-infected patients. In the first phase of the
study, 15 participants received four weeks of lefitolimod (MGN1703) therapy
(60 mg s.c. twice weekly). The extension phase will include 10-11 more
patients who will be treated for six months with lefitolimod. During the
treatment period, each participant will be closely monitored for the safety
and therapeutic effects of the drug. Aarhus University Hospital, Aarhus,
Denmark is conducting the trial in two hospital centers in Denmark and
already received funding from the American Foundation for AIDS research
(amfAR). MOLOGEN is providing the immunomodulator lefitolimod (MGN1703).

The primary endpoint of the study is the change in proportions of activated
natural killer cells in the patients. Secondary study endpoints include,
among others, a collection of safety, virological, immunological and
pharmacodynamic data.

HIV infects the immune system and destroys or affects the proper function
of immune cells. Without antiretroviral treatment this eventually leads to
immune deficiency and the immune system can no longer fight off a wide
range of infections and diseases. HIV remains a serious worldwide health
issue. According to estimates by WHO and UNAIDS (United Nations Programme
on AIDS) 37 million people worldwide were living with HIV at the end of
2014. Some 2 million people became newly infected in that same year, and
1.2 million died as a result of HIV-related causes globally.

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the